Amuc Protein Active Akkermansia
What is Amuctive™ ?
Amuctive™ Akkermansia, launched to the global market after years of R&D, represents Amuc + Active — a next-generation innovation emphasizing Akkermansia’s core active component, the Amuc_1100 protein.
Amuctive = Amuc_1100 Protein + Active
Amuc_1100 is the key to Akkermansia’s benefits—choose products validated for it.
Patented Amuc Protein Enrichment & Detection Technology
Developed a unique LC-MS method for precise Amuc_1100 quantification, achieving over 3× higher levels than conventional Akkermansia products.
SA-GRAS Certified Safety
Fully validated through systematic toxicology and clinical trials.
10+ Global Patents
Comprehensive IP coverage spanning production processes, detection methods, and formulations.
About Akkermansia
Akkermansia muciniphila is a specialized, mucin-degrading bacterium that resides in the mucus layer of the human digestive tract, making up 1%-5% of the microbiome in healthy people. It is considered a "keystone" species of the gut microbiome and a leading candidate for next-generation probiotics due to its influence on metabolic health and immune regulation.
Accumulating evidence shows Akkermansia helps maintain intestinal barrier integrity, fine-tune host immune response, and enhance multiple metabolic pathways. Compared to traditional probiotics, Akkermansia stands out as a most promising next-generation probiotic and first microbes for clinical use.
Health Benefits
Lower Akkermansia Levels Link to Poor Health
Scientific research has shown that Akkermansia plays a beneficial role in protecting the gut barrier and reducing insulin resistance. Insufficient or reduced levels of Akkermansia have been associated with various metabolic disorders, often accompanied by a thinner mucus layer and impaired gut barrier function. On the contrary, when Akkermansia is present in the gut, it contributes to a stronger gut lining.
Am J Physiol Endocrinol Metab. 2019 Sep 1;317(3):E446–59.
Regulates Postprandial Blood Glucose
A 12-week clinical trial involving 76 patients with type 2 diabetes (T2D) showed that daily oral intake of a five-strain formula containing Akkermansia significantly reduced postprandial glucose AUC by 36 mg/dL and HbA1c by 0.6%, with no adverse reactions reported.
BMJ Open Diabetes Res Care. 2020;8(1):e001319.
Reduces Body Obesity
In a clinical study of 58 overweight/obese T2D subjects, those with low baseline Akkermansia levels who received Akkermansia supplementation (1–5×10¹⁰ CFU/day) demonstrated high colonization efficiency and experienced significant reductions in body weight, fat mass, and HbA1c.
Cell Metab. 2025;37(3):592-605.e6.
Alleviates Insulin Resistance
A 3-month trial with 40 overweight volunteers with insulin resistance found that daily intake of inactivated Akkermansia (1×10¹⁰ cells/day) notably improved insulin sensitivity (+28.62±7.02%), and reduced insulinaemia (−34.08±7.12%) and total cholesterol levels (−8.68±2.38%).
Nat Med. 2019;25(7):1096-1103.
Scientific research has shown that Akkermansia plays a beneficial role in protecting the gut barrier and reducing insulin resistance. Insufficient or reduced levels of Akkermansia have been associated with various metabolic disorders, often accompanied by a thinner mucus layer and impaired gut barrier function. On the contrary, when Akkermansia is present in the gut, it contributes to a stronger gut lining.
Am J Physiol Endocrinol Metab. 2019 Sep 1;317(3):E446–59.
A 12-week clinical trial involving 76 patients with type 2 diabetes (T2D) showed that daily oral intake of a five-strain formula containing Akkermansia significantly reduced postprandial glucose AUC by 36 mg/dL and HbA1c by 0.6%, with no adverse reactions reported.
BMJ Open Diabetes Res Care. 2020;8(1):e001319.
In a clinical study of 58 overweight/obese T2D subjects, those with low baseline Akkermansia levels who received Akkermansia supplementation (1–5×10¹⁰ CFU/day) demonstrated high colonization efficiency and experienced significant reductions in body weight, fat mass, and HbA1c.
Cell Metab. 2025;37(3):592-605.e6.
A 3-month trial with 40 overweight volunteers with insulin resistance found that daily intake of inactivated Akkermansia (1×10¹⁰ cells/day) notably improved insulin sensitivity (+28.62±7.02%), and reduced insulinaemia (−34.08±7.12%) and total cholesterol levels (−8.68±2.38%).
Nat Med. 2019;25(7):1096-1103.
Clinical Summary
The Impact of Amuctive™ Supplementation on Weight Management
Enrolled: 16 adults taking one capsule daily (30 billion CFU) for 3 months
Dosage: 30B CFU Amuctive
Trial Cycle: 90 Days
Detection Indicators: Body weight, BMI, waist and abdominal circumference, waist-to-hip ratio, total cholesterol, fasting glucose, triglycerides, liver function.
Result: Amuctive showed significant improvements in body measurements and key metabolic markers, demonstrating clear benefits for weight management and metabolic health.
The Impact of Amuctive™ Supplementation on Hypercholesterolemia
Enrolled: 60 adults aged 40–60 years with hyperlipidemia and overweight/obesity
Intervention: Amuctive AKK vs Placebo
Dosage: 34B TFU/day Amuctive
Trial Cycle: 3 months
Detection Indicators: Total cholesterol (TC), LDL-C, triglycerides (TG), HDL-C, fasting blood glucose (FBG), insulin, HbA1c, waist circumference, BMI, liver/kidney function, and adverse events (AE/SAE).
Baseline-Dependent Effects of Akkermansia Supplementation in Type 2 Diabetes
Enrolled: 58 participants with overweight or obese T2D
Dosage: 15*10^10 CFU/g/day Akkermansia muciniphila
Control Group: Placebo
Trial Cycle: 12 Weeks
Detection Indicators: Body weight, Plasma glucose levels, Gut microbiome, HbA1c levels, Serum insulin levels, GLP-1 levels, Lipid metabolism, Safety outcomes
Result: In participants with low baseline A. muciniphila, Akkermansia supplementation showed high colonization efficiency and significant reductions in body weight, fat mass, and HbA1c, which were not found in the placebo group.
DOI: 10.1016/j.cmet.2024.12.010 (AKK-WST01)
Clinical Evaluation of Pasteurized Akkermansia Supplementation on Metabolic Health in Overweight Adults
Enrolled: 32 overweight/obese insulin resistant volunteers
Dosage: 10 billion/day liver or pasteurized A. muciniphila
Control Group: Placebo
Trial Cycle: 3 Months
Detection Indicators: Safety, Tolerability, Metabolic parameters, Gut barrier function, Gut microbiota composition
Result: Compared with placebo, pasteurized akkermansia improved insulin sensitivity, reduced insulinemia and plasma total cholesterol after 3 months (p<0.05). Meanwhile, akkermansia reduced the levels of relevant blood markers of liver dysfunction and inflammation while the overall gut microbiome structure was unaffected.
DOI: 10.1038/s41591-019-0495-2
Available in
Tablets
Hard Capsule
Soft Capsule
Powders
Beverages
Gummies
Liquids
Recommended Formulation
Berberine/Dihydroberberine
Lipid Metabolism:
Beberine and dihydroberberine can improve the abundance of Akkermansia to regulate lipid metabolism.
L-Ergothioneine
Healthy Aging:
Akkermansia can improve lifespan by 15-20% and physiological function, while L-ergothioneine can be distributed to liver, brain and other organs through OCTN1 protein to play an anti-aging role.
Urolithin A
Metabolism Health:
Urolithin A can improve the gut abundance of Akkermansia to enchance the function of liver and kidney.
Quality Assurance
NON-GMO
ISO 9001
Gluten Free
BSE Free
Halal Certified
Kosher Certified
HACCP
ISO 22000
Frequently asked questions
What clinical backing does Amuctive AKKermansia have?
What is the Amuc_1100 protein?
What advantages does Amuctive have compared to other Akkermansia strains?
As the main active component, how resistant is Amuc_1100 to gastric acid?
What is the recommended dosage for Amuctive?
Recommend Products
RequestSample
Leave Word
Have further questions? Our friendly experts will get back to you within 24 hours to assist you further
+1(425)866-9043
sales@bonerge.com